alexa The North American experience with stereotactic body radiation therapy in non-small cell lung cancer.
Cardiology

Cardiology

Atherosclerosis: Open Access

Author(s): Timmerman RD, Park C, Kavanagh BD

Abstract Share this page

Abstract INTRODUCTION: In North America, the majority of prospective investigation using stereotactic body radiation therapy (SBRT) for thoracic targets has been carried out treating medically inoperable patients with non-small cell lung cancer. METHODS: Because SBRT involves constructing very compact high-dose volumes within the lung for targeting cancer deposits, tumor position must be accurately assessed throughout the respiratory cycle. Measures to account for this motion, either by tracking (chasing), gating, or inhibition (breath hold and abdominal compression) must be used to avoid large margins of error that would expose uninvolved normal tissues. Sophisticated image guidance and related treatment delivery technology have been used primarily for the purpose of targeting the tumor with as low a radiation dose to the surrounding normal tissue as possible. RESULTS: Phase I dose escalation trials have been carried out in North America to achieve potent tumorcidal dose levels capable of eradicating tumors with high likelihood. These studies indicate a clear dose-response relationship for tumor control with escalating dose of SBRT. While late toxicity requires further careful assessment, acute and subacute toxicity are generally acceptable. Radiographic and local tissue effects consistent with bronchial or vascular damage and downstream collapse with fibrosis are common. While such radiographic changes are most often asymptomatic, more frequent and sometimes debilitating toxicity has been observed for patients with tumors near the central airways. CONCLUSIONS: Prospective trials using SBRT in North America have been able to identify potent tolerant dose levels and confirm their efficacy in patients with medically inoperable disease. Although mechanisms of this injury remain elusive, ongoing prospective trials offer the hope of finding the ideal application for SBRT in treating pulmonary targets. This article was published in J Thorac Oncol and referenced in Atherosclerosis: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords